Trastuzumab duocarmazine
In clinical developmentAlso known as Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxyb.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- The Lancet. Oncology1
- Aftimos P1
- Banerji U1
- Boni V1
- de Vries EGE1
- Eskens F1
- Geenen J1
- Gil-Martin M1
- Koper NP1
- Beatson West of Scotland Cancer Center1
- Erasmus Medical Center1
- Ghent University Hospital1
- Institut Català d'Oncologia-IDIBELL1
- Institut Jules Bordet-Université Libre de Bruxelles1
- Institute of Cancer Research and The Royal Marsden1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials